Caladrius Biosciences to Present at the BIO CEO & Investor Conference
Caladrius Biosciences (NASDAQ: CLBS) announced that CEO David J. Mazzo, PhD, will present a corporate overview at the 2022 BIO CEO & Investor Conference in New York City on February 14-15 and virtually through February 17. Registered attendees can access the presentation on-demand starting February 11. Caladrius is focused on developing innovative therapies, including XOWNA® (CLBS16) for coronary microvascular dysfunction, and is advancing clinical trials for other product candidates like CLBS12 and CLBS201. For more details, visit www.caladrius.com.
- None.
- None.
BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.
Dr. Mazzo’s presentation will be available to registered attendees on-demand through the event platform beginning February 11. For more information about the conference and how to register, please visit https://www.bio.org/events/bio-ceo-investor-conference/sessions/887473.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include: XOWNA® (CLBS16), the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of orphan designation for Buerger’s Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of CLI and Buerger’s Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for DKD. For more information on the Company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com
FAQ
What is the upcoming conference for Caladrius Biosciences in 2022?
Who will represent Caladrius at the BIO CEO & Investor Conference?
When will the presentation by Caladrius' CEO be available?
What are the main products being developed by Caladrius Biosciences?
What is XOWNA® (CLBS16) being tested for?
